Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy

Human Gene Therapy

Volumn 17, Issue 2, 2006, Pages 147-157

  Green, Katie L ^a   Southgate, Tom D ^b   Mulryan, Kate ^b   Fairbairn, Lez J ^b   Stern, Peter L ^b   Gaston, Kevin ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN VP22; TRANSCRIPTION FACTOR E2A; VIRUS FUSION PROTEIN; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER GENETICS; CELL KILLING; GENE THERAPY; GROWTH INHIBITION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; TARGET CELL; TUMOR MODEL; UTERINE CERVIX CANCER; VIRUS EXPRESSION; WART VIRUS;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BYSTANDER EFFECT; CULTURE MEDIA, CONDITIONED; DIFFUSION; DNA-BINDING PROTEINS; FEMALE; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; RECOMBINANT FUSION PROTEINS; UTERINE CERVICAL NEOPLASMS; VIRAL STRUCTURAL PROTEINS; VIRUS REPLICATION;

ADENOVIRIDAE; CANCER VIRUS; HUMAN HERPESVIRUS 1; HUMAN PAPILLOMAVIRUS TYPES;

EID: 32944461979     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.147     Document Type: Article

References (34)

1. BASTA, A., ADAMEK, K., and PITYNSKI, K. (1999). Intraepithelial neoplasia and early stage vulvar cancer: Epidemiological, clinical and virological observations. Eur. J. Gynaecol. Oncol. 20, 111-114.
2. BECHTOLD, V., BEARD, P., and RAJ, K. (2003). Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J. Virol. 77, 2021-2028.
3. BRAY, F., SANKILA, R., FERLAY, J., and PARKIN, D.M. (2002). Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer 38, 99-166.
4. DAVIDSON, E.J., BROWN, M.D., BURT, D.J., PARISH, J.L., GASTON, K., KITCHENER, H.C., STACEY, S.N., and STERN, P.L. (2001). Human T cell responses to HPV 16 E2 generated with monocyte derived dendritic cells. Int. J. Cancer 94, 807-812.
5. DELL, G., and GASTON, K. (2001). Human papillomaviruses and their role in cervical cancer. Cell. Mol. Life Sci. 58, 1923-1942.
6. DESAINTES, C., DEMERET, C., GOYAT, S., YANIV, M., and THIERRY, F. (1997). Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J. 16, 504-514.
7. DOWHANICK, J.J., MCBRIDE, A.A., and HOWLEY, P.M. (1995). Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol. 69, 7791-7799.
8. ELLIOTT, G., and O'HARE, P. (1999). Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 6, 149-151.
9. ELLIOTT, G., O'REILLY, D., and O'HARE, P. (1996). Phosphorylation of the herpes simplex virus type 1 tegument protein VP22. Virology 226, 140-145.
10. ELLIOTT, G., O'REILLY, D., and O'HARE, P. (1999). Identification of phosphorylation sites within the herpes simplex virus tegument protein VP22. J. Virol. 73, 6203-6206.
11. ELLIOTT, G.D., and MEREDITH, D.M. (1992). The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49. J. Gen. Virol. 73, 723-726.
12. FANG, B., XU, B., KOCH, P., and ROTH, J.A. (1998). Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Ther. 5, 1420-1424.
13. FRANCIS, D.A., SCHMID, S.I., and HOWLEY, P.M. (2000). Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J. Virol. 74, 2679-2686.
14. HARDY, S., KITAMURA, M., HARRIS-STANSIL, T., DAI, Y., and PHIPPS, M.L. (1997). Construction of adenovirus vectors through Cre-fox recombination. J. Virol. 71, 1842-1849.
15. HUBERT, P., VAN DEN, B.F., GIANNINI, S.L., FRANZEN-DETROOZ, E., BONIVER, J., and DELVENNE, P. (1999). Colonization of in vrtro-formed cervical human papillomavirus-associated (pre)neoplastic lesions with dendritic cells: Role of granulocyte/macrophage colony stimulating factor. Am. J. Pathol. 154, 775-784.
16. HWANG, E.S., RIESE, D.J., II, SETTLEMAN, J., NILSON, L.A., HONIG, J., FLYNN, S., and DIMAIO, D. (1993). Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J. Virol. 67, 3720-3729.
17. LEIFERT, J.A., and WHITTON, J.L. (2003). "Translocatory proteins" and "protein transduction domains": A critical analysis of their biological effects and the underlying mechanisms. Mol. Ther. 8, 13-20.
18. LUNDBERG, M., and JOHANSSON, M. (2001). Is VP22 nuclear homing an artifact? Nat. Biotechnol. 19, 713-714.
19. MICHEL, N., OSEN, W., GISSMANN, L., SCHUMACHER, T.N., ZENTGRAF, H., and MULLER, M. (2002). Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294, 47-59.
20. MILLER, C.S., and JOHNSTONE, B.M. (2001). Human papillomavirus as a risk factor for oral squamous cell carcinoma: A meta-analysis, 1982-1997. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 91, 622-635.
21. MUNGER, K., PHELPS, W.C., BUBB, V., HOWLEY, P.M., and SCHLEGEL, R. (1989). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417-4421.
22. PHELAN, A., ELLIOTT, G., and O'HARE, P. (1998). Intercellular delivery of functional p53 by the herpesvirus protein VP22, Nat. Biotechnol. 16, 440-443.
23. RITTER, T., LEHMANN, M., and VOLK, H.D. (2002). Improvements in gene therapy: Averting the immune response to adenoviral vectors. Biodrugs 16, 3-10.
24. ROEDER, G.E., PARISH, J.L., STERN, P.L., and GASTON, K. (2004). Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. Biotechnol. Appl. Biochem. 40, 157-165.
25. RUTJES, S.A., BOSMA, P.J., ROHN, J.L., NOTEBORN, M.H., and WESSELING, J.G. (2003). Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal apoptin-VP22 fusion proteins. J. Mol. Med. 81, 558-565.
26. SANCHEZ-PEREZ, A.M., SORIANO, S., CLARKE, A.R., and GASTON, K. (1997). Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis. J. Gen. Virol. 78, 3009-3018.
27. STROH, C., HELD, J., SAMRAJ, A.K., and SCHULZE-OSTHOFF, K. (2003). Specific inhibition of transcription factor NF-κB through intracellular protein delivery of IκBα by the herpes virus protein VP22. Oncogene 22, 5367-5373.
28. TAN, S.H., GLOSS, B., and BERNARD, H.U. (1992). During negative regulation of the human papillomavirus-16 E6 promoter, the viral E2 protein can displace Sp1 from a proximal promoter element. Nucleic Acids Res. 20, 251-256.
29. TAN, S.H., LEONG, L.E., WALKER, P.A., and BERNARD, H.U. (1994). The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J. Virol. 68, 6411-6420.
30. VALDEZ GRAHAM, V., SUTTER, G., JOSE, M.V., GARCIA-CARRANCA, A., ERFLE, V., MORENO, M.N., MERCHANT, H., and ROSALES, R. (2000). Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer 88, 1650-1662.
31. WALBOOMERS, J.M., JACOBS, M.V., MANOS, M.M., BOSCH, F.X., KUMMER, J.A., SHAH, K.V., SNIJDERS, P.J., PETO, J., MEIJER, C.J., and MUNOZ, N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19.
32. WEBSTER, K., PARISH, J., PANDYA, M., STERN, P.L., CLARKE, A.R., and GASTON, K. (2000). The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J. Biol. Chem. 275, 87-94.
33. YEE, C., KRISHNAN-HEWLETT, I., BAKER, C.C., SCHLEGEL, R., and HOWLEY, P.M. (1985). Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119, 361-366.
34. ZAVAGLIA, D., FAVROT, M.C., EYMIN, B., TENAUD, C., and COLL, J.L. (2003). Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein. Gene Ther. 10, 314-325.